勃林格殷格翰携手京东健康达成全域战略合作,共塑宠物健康数字化新未来 勃林格殷格翰携手京东健康达成全域战略合作,共塑宠物健康数字化新未来 勃林格殷格翰携手京东健康达成全域战略合作,共塑宠物健康数字化新未来
供应商行为准则 供应商行为准则 BI's expectations towards its suppliers on ethical behavior, integrity, professionalism and common business requirements.
我们的预期 我们的预期 We expect adherence to exemplary ethical and professional conduct both within the company and from our business partners.
劳工与人权 劳工与人权 Suppliers shall support and respect the protection of internationally proclaimed human rights.
环境 环境 Suppliers shall operate in an environmentally responsible and efficient manner to minimize adverse impacts on the environment.
健康与安全 健康与安全 Suppliers shall provide a safe and healthy working environment and shall operate environmentally responsible and sustainable.
管理体制 管理体制 Suppliers shall use management systems to support continuous improvement and compliance with the Supplier Code of Conduct.
提出问题或担忧 提出问题或担忧 Supplier must report ethics and compliance concerns that might affect Boehringer Ingelheim.
Download the Supplier Code of Conduct Download the Supplier Code of Conduct Our Values - Your Values. Download the Supplier Code of Conduct.
勃林格殷格翰旗下用于治疗HER2突变非小细胞肺癌药物宗艾替尼获FDA局长国家优先审评券 勃林格殷格翰旗下用于治疗HER2突变非小细胞肺癌药物宗艾替尼获FDA局长国家优先审评券 勃林格殷格翰旗下用于治疗HER2突变非小细胞肺癌药物宗艾替尼获FDA局长国家优先审评券
宗艾替尼在HER2(ERBB2)突变晚期非小细胞肺癌(NSCLC)初治患者中显示出77%的客观缓解率 宗艾替尼在HER2(ERBB2)突变晚期非小细胞肺癌(NSCLC)初治患者中显示出77%的客观缓解率 宗艾替尼在HER2(ERBB2)突变晚期非小细胞肺癌(NSCLC)初治患者中显示出77%的客观缓解率
美国FDA批准勃林格殷格翰JASCAYD®(nerandomilast)成为十余年来首个特发性肺纤维化新疗法 美国FDA批准勃林格殷格翰JASCAYD®(nerandomilast)成为十余年来首个特发性肺纤维化新疗法 美国FDA批准勃林格殷格翰JASCAYD®(nerandomilast)成为十余年来首个特发性肺纤维化新疗法
Supplier Code of Conduct 2025 ZH simple Supplier Code of Conduct 2025 ZH simple Supplier Code of Conduct 2025 ZH simple
勃林格殷格翰在ERS上公布FIBRONEER项目汇总分析数据:nerandomilast单药治疗与特发性肺纤维化和进展性肺纤维化患者死亡风险名义显著降低相关 勃林格殷格翰在ERS上公布FIBRONEER项目汇总分析数据:nerandomilast单药治疗与特发性肺纤维化和进展性肺纤维化患者死亡风险名义显著降低相关 勃林格殷格翰在ERS上公布FIBRONEER项目汇总分析数据:nerandomilast单药治疗与特发性肺纤维化和进展性肺纤维化患者死亡风险名义显著降低相关
请扫码关注我们
勃林格殷格翰官方
勃林格殷格翰HR
勃林格殷格翰动保